| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Cytarabine | CTRPv2 | pan-cancer | AAC | 0.16 | 3e-08 |
| mRNA | ceranib-2 | CTRPv2 | pan-cancer | AAC | 0.17 | 1e-07 |
| mRNA | LY-2183240 | CTRPv2 | pan-cancer | AAC | 0.16 | 3e-07 |
| mRNA | NPK76-II-72-1 | GDSC1000 | pan-cancer | AAC | 0.16 | 3e-07 |
| mRNA | 17-AAG | GDSC1000 | pan-cancer | AAC | -0.16 | 9e-07 |
| mRNA | clofarabine | CTRPv2 | pan-cancer | AAC | 0.14 | 1e-06 |
| mRNA | GSK1070916 | GDSC1000 | pan-cancer | AAC | 0.16 | 1e-06 |
| mRNA | NVP-231 | CTRPv2 | pan-cancer | AAC | 0.15 | 2e-06 |
| mRNA | WZ3105 | GDSC1000 | pan-cancer | AAC | 0.15 | 2e-06 |
| mRNA | doxorubicin:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.15 | 2e-06 |